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Oral Presentations S235Table. (Continued )Total (%)Yes 6 (16%)
No 31 (84%)
Myeloablative Conditioning 37 (100%)
Graft Source
UCB 9 (24%)
MRD 15 (41%)
MURD 7 (19%)
MMURD 6 (16%)
HLA Match
Match 20 (54%)
Mismatch 17 (46%)
CSA containing GVHD Prophylaxis
Yes 29 (78%)
No 8 (22%)*Cytogenetics not available for 1 patient
Results: Neutrophil engraftment occurred in 89% of patients at
a median of 23 days (range 12-40). Patients transplanted after
year 1999 were more likely to engraft (RR 2.27, p 5 .04). Overall
survival (OS) was 70% and 53% at 1 and 3 years. In multivariate
analysis (MVA), OS was increased in patients who did not receive
pre HSCT chemotherapy (RR 0.04, p 5 .01) and decreased in
those with an IPSS score of Int-2 (RR 11.96, p 5 .03). Disease
free survival (DFS) was 62% and 48% at 1 and 3 years. In MVA,
factors associated with improved DFS at 3 years include having sec-
ondary MDS (RR 0.13, p 5 .02), undergoing HSCT after 1999 (p
5 .02 at 3 years), not receiving pre HSCT chemotherapy (RR 0.06,
p\.01), and a short interval (\140 days) from diagnosis to trans-
plant (RR 0.21, p 5 .03). Those with an IPSS score of Int-2 had
a significantly lower DFS (RR 3.96, p 5 .03). WHO classification,
cytogenetics and pre HSCT blast percentage had no significant im-
pact on either OS or DFS. The relapse rate at 2 years was 20%.
Factors associated with decreased relapse include having secondary
MDS (RR 0.04, p\.01) and not receiving pre HSCT chemotherapy
(RR 0.21, p 5 .03). Treatment-related mortality (TRM) was 25%
at 1 year. The risk of TRM was increased in patients with a pre
HSCT blast count $ 5% (RR 6.65, p 5 .01) and was decreased
in patients who did not receive pre HSCT chemotherapy (RR
0.07, P 5 .02). At 100 days the cumulative incidence of grades
II-IV and III-IV acute graft versus host disease (GVHD) was
40% and 16%, respectively. The incidence of chronic GVHD at
one year was 19%.
Conclusions: Our results suggest that in order to achieve optimal
outcomes, children with MDS should be referred for allogeneic
HSCT soon after diagnosis and that unlike in adult MDS, pre
HSCT chemotherapy does not appear to improve outcomes.87
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Background:Children with poor response acute myeloid leukaemia
(AML) or refractory AML are generally considered to have a very
poor outcome. Allogeneic stem cell transplantation (SCT) has
been recommended for these children however, the advantage of
SCT as opposed to continuous chemotherapy is not clear. Theaim of this study was to investigate survival for poor response
AML patients treated with SCT.
Procedure: The patients were treated according to the NOPHO-
AML 2004 protocol and data were collected from the NOPHO-
AML database. All patients received AIET (Cytarabine, Idarubicin,
Etoposide, Thioguanine) and AM (Cytarabine, Mitoxantrone) as
induction therapy. Poor response was defined as more than 15%
blasts on day 15 after AIET and/or .5% blasts after AM. These
patients proceeded to allo-SCT if a donor (family or unrelated)
was available.
Results:Twenty-five of 230 patients had a poor response. SCT was
performed in 21, using unrelated donors in 16, matched sibling do-
nors (MSD) in 4 and a haploidentical donor in one of the transplants.
Themedian follow-up was 2.9 years (range 0.7-7.3) and 3-year prob-
ability of survival 89%. Of five patients with more than 5% blasts at
time of SCT four remain alive.
Conclusions: The poor responders had a significantly better prog-
nosis than has previously been reported for patients with high blast
count on day 15 and it seems that SCT is the treatment of choice
for children with poor response AML.STEM CELL BIOLOGY88
EGF SIGNALING REGULATES HEMATOPOIETIC REGENERATION FOL-
LOWING TOTAL BODY IRRADIATION
Doan, P.L.1, Russell, J.L.1, Himburg, H.A.1, Helms, K.1, Sullivan, J.M.2,
Jeffords, L.B.2, Chao, N.J.1,4, Kirsch, D.G.2,3, Chute, J.P.1,3 1Duke Uni-
versity Medical Center, Durham, NC; 2Duke University Medical Center,
Durham, NC; 3Duke University Medical Center, Durham, NC; 4Duke
University Medical Center, Durham, NC
VEGFR2+ sinusoidal endothelial cells are necessary for normal
hematopoietic reconstitution following myelosuppressive chemo-
or radiotherapy (Hooper et al, Cell Stem Cell 2009). However, the
mechanisms through which BM endothelial cells promote HSC re-
generation remain unknown.We developed a mouse model in which
mice bearing cell-specific deletion of Bak and Bax in Tie2+ cells
(Tie2Cre;Bak1-/-;BaxFl/- mice) were irradiated with sublethal and
lethal doses of total body irradiation to assess whether protection
of BM Tie2+ ECs from radiation-induced apoptosis could protect
the hematopoietic compartment from myeloablative toxicity.
Tie2Cre;Bak1-/-;BaxFL/- mice demonstrated protection of BM
HSCs and 100% survival following lethal dose TBI (750 cGy),
whereas mice that retained Bax expression in Tie2+ cells demon-
strated depletion of BM HSCs and only 10% survival (p\0.0001).
To determine the mechanism through which Tie2+ BM ECs regu-
late HSC regeneration, we performed a cytokine array screen of
BM serum from Tie2Cre;Bak1-/-;BaxFl/- mice and compared with
Tie2Cre;Bak1-/-;BaxFl/+ mice and C57Bl6 mice. Among several
genes which were up- or down-regulated in the BaxFl/- mice, we
found an 18-fold increase in the concentration of epidermal growth
factor (EGF) compared to BaxFl/+ and C57Bl6 mice (p5 0.04). We
then showed that BM ECs express EGFR and BM ckit+sca-1+lin-
cells also express EGF in C57Bl6 mice. Interestingly, antibody
blockade of EGF in vitro blocked the ability of BaxFl/- ECs to sup-
port HSC regeneration following 300 cGy irradiation. Furthermore,
systemic administration of EGF to irradiatedmice caused a profound
recovery of BMHSC and progenitor cells compared to saline treated
control mice. Similarly, administration of erlotinib, an EGFR antag-
onist, caused a significant delay in recovery of BMHSCs in mice fol-
lowing high dose irradiation. Mechanistic studies revealed that
treatment of HSCs with EGF significantly increased EGFR phos-
phorylation and downstream activation of Akt signaling. Further-
more, inhibition of Akt signaling blocked the beneficial effect of
EGF in mediating the recovery of HSCs following radiation expo-
sure, suggesting that EGF action on HSC regeneration was medi-
ated by Akt activation. These data demonstrate that EGF is an
important regulator of HSC regeneration in vivo and a potential
new target for therapies to accelerate hematopoietic reconstitution
following chemotherapy and radiation exposure.
